You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL

    SBC: Actinium Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Despite treatment advances, the prognosis of adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and R/R diffuse large B-cell lymphoma (DLBCL) remains poor. Autologous T- cells modified to express a CD19-targeted chimeric antigen receptor (CAR T-cells) produce durable responses in subgroups of these patients, which has led to FDA approval of two su ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum

    SBC: STEM CULTURES LLC            Topic: 400

    Scientific Abstract: The frequent use of fetal bovine serum (FBS) to support cell cultures is challenged by lot-to-lot variability, supply constraints, pathogen contaminants and ethical questions. These issues have increased significance due to the burgeoning use of FBS in cell research and therapy development. FBS has been used for over a century to culture cells, but with the need to define cult ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Improved Treatment of Colorectal Cancer with CF10

    SBC: Deep Creek Pharma, LLC            Topic: 102

    PROJECT SUMMARY Decades of modulating the anti-cancer activity of fluoropyrimidine drugs (FPs) thru schedule optimization, biochemical modulation, and drug combinations have provided a significant, but limited, survival advantage for treating colorectal cancer (CRC) patients with locally advanced or metastatic disease (mCRC). However, outcomes remain poor for patients with mCRC and since targeted ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an Educational Product for Accelerating Solutions for Commercialization and Entrepreneurial Development (ASCEND) in Western IDeA States

    SBC: NEW MEXICO START-UP FACTORY II LLC            Topic: NIGMS

    Project Summary As a participant in the new IDeA Regional Entrepreneurship Development (I-RED) program, the goal of this proposal is to create an educational product to promote entrepreneurism and commercialization in the Mountain West region of IDeA states. The educational product and overall program are intended to address the needs of IDeA state academic institutions in developing and strengthe ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. CN-105 Improves Functional Outcome After Intracranial Hemorrhage

    SBC: AegisCN LLC            Topic: 106

    Annually, approximately 100,000 patients in the USA suffer from intracerebral hemorrhage (ICH), which is associated with high mortality rates and poor long-term cognitive and physical recovery. At present, no pharmacological therapies have been demonstrated to improve functional outcomes after ICH. However, we have successfully demonstrated that CN-105, a pentapeptide derived from the receptor bin ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD

    SBC: RIP ROAD, INC.            Topic: NIA

    Project SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. An Interactive Education Program to Reduce High Risk Behavior in Adolescents

    SBC: KLEIN BUENDEL, INC.            Topic: NICHD

    Internet-based TRAC (i-TRAC): Interactive Emotion Regulation Skills Training to Improve AdolescentSexual Health Adolescence is a critical developmental period during which behavioral patterns are formed that have powerful influences on current and future health. This is particularly true for sexual behavior, which is affected by the biological changes of puberty as well as normative developmental ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma

    SBC: ROCK IMMUNE LLC            Topic: 102

    Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skinlesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are thetwo most common types of CTCL. Although treatments exist, they are mainly palliative with low response anddurability of response without any cure. The objective response rate rem ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin

    SBC: POP Biotechnologies Inc.            Topic: NCI

    Summary Our goal is to commercialize interstitial chemo-phototherapy (I-CPT) as a new therapeutic option for locally advanced liver cancers. Doxorubicin (Dox) can be actively loaded into long circulating, serum-stable, porphyrin- phospholipid (PoP) liposomes and be released with 665-nm laser light (PhotoDox). This approach leads to vastly enhanced drug accumulation in irradiated tissues, resulting ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Teleconsent: Enabling informed consent for remote care and research

    SBC: Doxy.me Inc.            Topic: 100

    PROJECT SUMMARY . Informed consent is legal and ethical requirement in health care and research that assures that individuals have the autonomy to make informed care and research decisions at their own volition, under no coercion or undue influence, and with reasonable understanding of the risks, benefits, and responsibilities of their decisions as they would in-person. Obtaining informed consent ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government